Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by equities research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Tuesday.
A number of other research analysts have also issued reports on the company. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $19.00 target price (up from $18.00) on shares of Karyopharm Therapeutics in a report on Friday, March 16th. Robert W. Baird set a $22.00 target price on Karyopharm Therapeutics and gave the company a “buy” rating in a report on Thursday, March 15th. HC Wainwright lifted their target price on Karyopharm Therapeutics to $26.00 and gave the company a “buy” rating in a report on Thursday, March 15th. Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the company a “buy” rating in a report on Thursday, March 15th. Finally, Canaccord Genuity lifted their target price on Karyopharm Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Monday, March 12th. Two research analysts have rated the stock with a sell rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $19.60.
Karyopharm Therapeutics (KPTI) opened at $15.32 on Tuesday. Karyopharm Therapeutics has a fifty-two week low of $7.48 and a fifty-two week high of $18.00.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, March 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.66) by ($0.14). The company had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $2.26 million. Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 89.62%. The company’s revenue for the quarter was up 3163.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.65) earnings per share. equities research analysts expect that Karyopharm Therapeutics will post -2.72 EPS for the current fiscal year.
In other Karyopharm Therapeutics news, EVP Christopher Brett Primiano sold 2,500 shares of Karyopharm Therapeutics stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.01, for a total transaction of $37,525.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $15.29, for a total value of $152,900.00. Following the sale, the chief executive officer now directly owns 522,143 shares of the company’s stock, valued at $7,983,566.47. The disclosure for this sale can be found here. Insiders have sold a total of 69,000 shares of company stock valued at $928,625 over the last ninety days. 14.71% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. MetLife Investment Advisors LLC purchased a new stake in Karyopharm Therapeutics during the 4th quarter worth about $146,000. Palo Alto Investors LLC lifted its holdings in Karyopharm Therapeutics by 1.3% during the 4th quarter. Palo Alto Investors LLC now owns 3,544,439 shares of the company’s stock worth $34,027,000 after buying an additional 45,854 shares during the last quarter. Millennium Management LLC increased its position in shares of Karyopharm Therapeutics by 17.8% during the fourth quarter. Millennium Management LLC now owns 436,836 shares of the company’s stock worth $4,194,000 after purchasing an additional 65,920 shares in the last quarter. Two Sigma Investments LP increased its position in shares of Karyopharm Therapeutics by 76.8% during the fourth quarter. Two Sigma Investments LP now owns 24,220 shares of the company’s stock worth $233,000 after purchasing an additional 10,520 shares in the last quarter. Finally, Deutsche Bank AG increased its position in shares of Karyopharm Therapeutics by 16.1% during the fourth quarter. Deutsche Bank AG now owns 188,373 shares of the company’s stock worth $1,806,000 after purchasing an additional 26,108 shares in the last quarter. 62.60% of the stock is owned by institutional investors.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.